A novel concurrent TMS‐fMRI method to reveal propagation patterns of prefrontal magnetic brain stimulation. Issue 11 (29th August 2018)

• Record Type: Journal Article
• Authors: Vink, Jord J. T.; Mandija, Stefano; Petrov, Petar I.; van den Berg, Cornells A. T.; Sommer, Iris E. C.; Neggers, Sebastiaan F. W.
• Is Part Of: Human brain mapping. Volume 39:Issue 11(2018)
• Page Start: 4580
• Page End: 4592
• Publication Date: 2018-08-29
• Subjects: concurrent TMS‐fMRI -- depression -- dorsolateral prefrontal cortex -- functional MRI -- major depressive disorder -- subgenual anterior cingulate cortex -- transcranial magnetic stimulation; Brain mapping -- Periodicals; 611.81
• DOI: 10.1002/hbm.24307
• Languages: English
• ISSNs: 1065-9471

Abstract

Abstract: Major depressive disorder (MDD) is a severe mental disorder associated with high morbidity and mortality rates, which remains difficult to treat, as both resistance and recurrence rates are high. Repetitive transcranial magnetic stimulation (TMS) of the left dorsolateral prefrontal cortex (DLPFC) provides a safe and effective treatment for selected patients with treatment‐resistant MDD. Little is known about the mechanisms of action of TMS provided to the left DLPFC in MDD and we can currently not predict who will respond to this type of treatment, precluding effective patient selection. In order to shed some light on the mechanism of action, we applied single pulse TMS to the left DLPFC in 10 healthy participants using a unique TMS‐fMRI set‐up, in which we could record the direct effects of TMS. Stimulation of the DLPFC triggered activity in a number of connected brain regions, including the subgenual anterior cingulate cortex (sgACC) in four out of nine participants. The sgACC is of particular interest, because normalization of activity in this region has been associated with relief of depressive symptoms in MDD patients. This is the first direct evidence that TMS pulses delivered to the DLPFC can propagate to the sgACC. The propagation of TMS‐induced activity from the DLPFC to sgACC may be an accurate biomarker for rTMS efficacy. Further research is required to determine whether this method can contribute to the selection of patients with treatment resistant MDD who will respond to rTMS treatment.